Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions

Hodgkin Lymphoma

Interventions

DRUG

Idelalisib

Idelalisib tablets administered orally

Trial Locations (3)

Memorial Sloan Kettering Cancer Center, New York

MD Anderson Cancer Center, Houston

Fred Hutchinson Cancer Research Center, Seattle